Evidence map›Paper›PMID 35743749›Full record

ReviewJournal of personalized medicine2022

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.

Zachary Braunstein, Miguel Ruiz, Walter Hanel, Polina Shindiapina, John C Reneau, Jonathan E Brammer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zachary BraunsteinWexner Medical Center, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-2517-9943
Miguel RuizWexner Medical Center, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Walter HanelJames Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Polina ShindiapinaJames Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
John C ReneauJames Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-6838-2410
Jonathan E BrammerJames Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL.

Indexed as

adult T-cell lymphomaangioimmunoblastic T-cell lymphomaleukemialymphomanovel therapyperipheral T-cell lymphomaperipheral T-cell lymphoma not otherwise specifiedrefractoryrelapsedT celltherapeutics

Identifiers

PMID35743749
PMCPMC9225101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.